Manufacturing consensus

Culture, Medicine and Psychiatry

Volumn 30, Issue 2, 2006, Pages 135-156

  Healy, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Adolescent depression; FDA; Manufacturing consensus; Pharmaceutical marketing; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ARTICLE; CONSENSUS; DEPRESSION; FOOD AND DRUG ADMINISTRATION; HUMAN; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CONSENSUS; DEPRESSION; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748310662     PISSN: 0165005X     EISSN: 1573076X     Source Type: Journal    
DOI: 10.1007/s11013-006-9013-3     Document Type: Article

References (39)

1. Alderman, J., R. Wolkow, M. Chung, and H.F. Johnston 1998 Sertraline Treatment of Children and Adolescents with OCD or Depression: Pharmacokinetics, Tolerability, and Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry 37: 386-394.
2. Ambrosini, P.J., K.D. Wagner, J. Biederman, I. Glick, C. Tan, J. Elia, J.R. Hebeler, H. Rabinovitch, J. Lock, and D. Geller 1999 Multicenter Open Label Sertraline Study in Adolescent Outpatients with Major Depression. Journal of the American Academy of Child and Adolescent Psychiatry 38: 566-572.
3. Applbaum, Kalman 2004 The Marketing Era. New York: Routledge.
4. Carpenter, D.J., G.J. Emslie, B. Birmaher et al. 2001 Safety of Paroxetine in the Treatment of Children and Adolescents with OCD. Presented at the 40th annual NCDEU meeting, abstract 58.
5. Chiles, J.A., A.L. Miller, and M.L. Crismon et al. 1999 The Texas Medication Algorithm Project: Development and Implementation of the Schizophrenia Algorithm. Psychiatric Services 50: 69-74.
6. Eccleston, D. 1993 The Economic Evaluation of Antidepressant Drug Therapy. British Journal of Psychiatry 163: Supplement 20.
7. Emslie, G.J., J.H. Heligenstein, K.D. Wagner, S.L. Hoog, D.E. Ernest, E. Brown, M. Nilsson, and J.G. Jacobson 2002 Fluoxetine for Acute Treatment in Children and Adolescents: A Placebo-Controlled Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry 41: 1205-1215.
8. Emslie, G., J.J. Mann, W. Beardslee, J. Fawcett, A. Leon, H. Meltzer, F. Goodwin, D. Shaffer, K. Wagner, and N. Ryan 2004 ACNP. Preliminary Report of the Task Force on SSRIs and Suicidal Behavior in Youth. January 21.
9. Emslie, G.J., A.J. Rush, A.W. Weinberg, R.A. Kowatch, C.W. Hughes, and T. Carmody 1997 A Double-Blind, Randomized Placebo Controlled Trial of Fluoxetine in Depressed Children and Adolescents. Archives of General Psychiatry 54: 1031-1037.
10. Flanagin, A., L.A. Carey, P.B. Fontanarosa, S.G. Phillips, B.P. Pace, G.D. Lundberg, and D. Rennie 1998 Prevalence of Articles with Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals. Journal of the American Medical Association 280: 222-224.
11. Garland, E. Jane 2004 Facing the Evidence: Antidepressant Treatment in Children and Adolescents. Canadian Medical Association Journal 170: 489-491.
12. Geller, D.A., K.D. Wagner, G.J. Emslie, T. Murphy, D. Gallagher, C. Gardiner, and D.J. Carpenter 2002 Efficacy and Safety of Paroxetine in Pediatric OCD: Results of a Double-Blind Placebo Controlled Trial. Presented at the 42nd Annual NCDEU Meeting, Session III-16. (Also presented at the APA annual meeting, Philadelphia, May 2002, NR 349.)
13. Gilbert, D.A., K.Z. Altshuler, W.V. Rego, S.P. Shon, M.L. Crismon, M.G. Toprac, and A.J. Rush 1998 Texas Medication Algorithm Project: Definitions, Rationale, and Methods to Develop Medication Algorithms. Journal of Clinical Psychiatry 59: 345-351.
14. Guest, J.F., W.M. Hart, R.F. Cookson, and E. Lindstrom 1996 Pharmacoeconomic Evaluation of Long-Term Treatment with Risperidone for Patients with Chronic Schizophrenia. British Journal of Medical Economics 10: 59-67.
15. Healy, David 1998 The Antidepressant Era. Cambridge, MA: Harvard University Press.
16. 2003a Let Them Eat Prozac. Toronto: Lorimer (Linked Web site: ttp://www.healyprozac.com).
17. 2003b Lines of Evidence on SSRIs and Risk of Suicide. Psychotherapy and Psychosomatics 72: 71-79.
18. 2004 Shaping the Intimate. Influences on the Experience of Everyday Nerves. Social Studies of Science 34: 219-245.
19. Healy, David, and Dinah Cattell 2003 The Interface between Authorship, Industry and Science in the Domain of Therapeutics. British Journal of Psychiatry 182: 22-27.
20. Healy, David, and David J. Nutt 1998 British Association for Psychopharmacology Consensus on Statement on Childhood and Learning Disabilities Psychopharmacology. Journal of Psychopharmacology 11: 291-294.
21. Herxheimer, Andrew, and Barbara Mintzes 2004 Antidepressants and Adverse Effects in Young Patients: Uncovering the Evidence. Canadian Medical Association Journal 170: 487-489.
22. Hughes, C.W. 1999 The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry 38: 1442-1454.
23. Keller, M.D., N.D. Ryan, M. Strober, R.G. Klein, S.P. Kutcher, B. Birmaher, O.R. Hagino, H. Koplewicz, G.A. Carlsson, G.N. Clarke, G.J. Emslie, D. Feinberg, B. Geller, V. Kusumakar, G. Papatheodorou, W.H. Sack, M. Sweeney, K.D. Wagner, E. Weller, N.C. Winters, R. Oakes, and J.P. McCafferty 2001 Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry 40: 762-772.
24. Khan, Arif, Shirin R. Khan, Robyn Leventhal, and Walter A. Brown 2001 Symptom Reduction and Suicide Risk in Patients Treated with Placebo in Antipsychotic Clinical Trials. American Journal of Psychiatry 158: 1449-1454.
25. Kuslak, V. 2003 Letter to Physicians. Wyeth Pharmaceuticals, August 22. Available at: http://www.rphlink.com/wyethpharmaceuticals.html.
26. Mandoki, M.W., M.R. Tapla, M.A. Tapla, G.S. Sumner, and J.L. Parker 1997 Venlafaxine in the Treatment of Children and Adolescents with Major Depression. Psychopharmacology Bulletin 33: 149-154.
27. March, J.S., J. Biederman, R. Wolkow, A. Safferman, J. Mardekian, E.H. Cook, N.R. Cutler, R. Dominguez, J. Ferguson, B. Muller, R. Riesenberg, M. Rosenthal, F.R. Sallee, K.D. Wagner, and H. Steiner 1998 Sertraline in Children and Adolescents with OCD: A Multicenter Randomized Controlled Trial. Journal of the American Medical Association 280: 1752-1758.
28. Mortimer, A., D. Healy, R. Gray, R. Peveler, P. Pratt, T. Sharma, and T. Turner 1998 Consensus Statement on Schizophrenia Standards in Care for Maintenance Therapy and Poorly Responding/Treatment Intolerant Patients. CINP meeting, Glasgow. International Journal of Neuropsychopharmacology 1:Abstracts Supplement.
29. Mosholder, Andrew 1993 Review and Evaluation of Clinical Data. Application NDA 20-272, 11 May. (Cited in J. Whitaker and R. Whitaker 2002. Mad in America. Boston: Perseus: 277).
30. National Institute for Clinical Excellence (NICE) 2002 Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43, June. Available at: http://www.nice.org.uk.
31. Newsweek 2002 Depression. 3 Million Kids Suffer From It. What You Can Do. Newsweek, October 7:52-61.
32. Petersen, Melody 2004 Making Drugs, Shaping the Rules. Big Pharma Is Eager to Help States Set Medication Guidelines. New York Times, February 1:3-1, 3-10.
33. Rosenheck, R., D. Perlick, S. Bingham, W.L. Mares, J. Collins, S. Warren, D. Leslie, E. Allan, C. Campbell, S. Caroff, J. Corwin, L. Davis, R. Douyon, L. Dunn, D. Evans, E. Frecska, J. Grabowski, D. Graeber, L. Herz, K. Kong, W. Lawson, F. Mena, J. Sheikh, D. Smelson, and V. Smith-Gamble 2003 Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia. A Randomized Controlled Trial. Journal of the American Medical Association 290: 2693-2702.
34. Sharav, Vera Hassner 2003 The Impact of FDA Modernization Act on the Recruitment of Children for Research. Ethical Human Sciences and Services: An International Journal of Critical Inquiry 5: 83-108.
35. Sheldon, T.A., and G.D. Smith 1993 Consensus Conferences as Drug Promotion. Lancet 341: 100-102.
36. Wagner, K.D., P. Ambrosini, M. Rynn, C. Wohlberg, R. Yang, M.S. Greenbaum, A. Childress, C. Donnelly, and D. Deas 2003 Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder: Two Randomized Controlled Trials. Journal of the American Medical Association 290: 1033-1041.
37. Wagner, K.D., E. Wetherhold, D.J. Carpenter, S. Krulewicz, and A. Bailey 2002 Safety and Tolerability of Paroxetine in Children and Adolescents: Pooled Results from Four Multi-center Placebo Controlled Trials. Presented at the 42nd Annual NCDEU Meeting, Session 11-61.
38. Walkup, J.T., M.J. Labellarte, M.A. Riddle, D.S. Pine, L. Greenhill, R. Klein, M. Davies, M. Sweeney, C. Fu, H. Abikoff, S. Hack, B. Klee, J. McCracken, L. Bergman, J. Piacentini, J. March, S. Compton, J. Robinson, T. O'Hara, S. Baker, B. Vitiello, L. Ritz, and M. Roper 2001 Fhivoxamine for the Treatment of Anxiety Disorders in Children and Adolescents. New England Journal of Medicine 344: 1279-1285.
39. World Health Organization 2003 Technology Appraisal Programme of the National Institute for Clinical Excellence. Geneva: WHO. Available at: http://www.nice.org.uk.